• CEO excellence and transition: Developed a comprehensive 10-year strategy plan for transitioning CEO of a top 10 pharma, navigating patent expiration and regulatory challenges through R&D acceleration and business development initiatives
• R&D acceleration: Crafted portfolio optimization strategy for a leading pharma company on pipeline acceleration and sharpened
focus of strategic TAs (e.g., oncology, cell therapy)
• Market entry and penetration: Orchestrated growth and market entry strategy for a MedTech company backed by life science-
focused PE fund, leading to successful IPO (~$400M)
• Portfolio strategy: Conducted comprehensive market analysis of Robotic surgery, cardiovascular devices, Neurology devices, Diagnostic Imaging and Orthopedic Devices to identify emerging trends, competitive landscape, and growth opportunities
• R&D Innovation: Formulated strategic recommendations for product innovation, market entry strategies, and portfolio expansion in in neuromodulation and robotic surgery space for a leading MedTech company
• Business Development: Identified externalization / licensing-in opportunities for a growing biopharma firm, expanding geographic (to APAC) and therapeutic areas presence (1 new TA while building depth in 2 TAs)
• Commercial due diligence: Led due diligence efforts, pinpointing strategic opportunities that led to successful acquisition of 3 biopharma companies to enhance neuroscience and oncology portfolios
• Commercial due diligence: Formulated market entry/asset acquisition strategy for leading logistic real estate company, leading to successful geographic expansion
• Vendor due diligence: Led life sciences-focused PE firm in acquiring a promising MedTech company (robotic surgery focused) through rigorous due diligence, financial analysis, and strategic evaluation
• Operation excellence: Designed and implemented a value-capturing strategy for a top 20 pharma to boost revenue while achieve
cost efficiencies to increase operating margin by 6%

• Spearheaded cross-functional teams in acquiring and managing hospitality properties for four real estate funds, accelerating expansion with a rate of 6 deals/month (compared to standard 1/month).
• Strategically refocused investment strategy on hospitality and tourism properties, yielding a 5.8% annual ROI increase amid currency exchange constraints
• Acquired properties below market value by 10%-15% through strategic negotiation and leveraging local agency relationships.
• Pioneered "sale-leaseback" strategy, tailoring asset allocation to investors' needs and elevating ROI from 13% to 25%
• Directed the redevelopment and refurbishment of four historical buildings in downtown Lisbon, implementing budget monitoring models that led to a 13% cost saving from initial projections.

Managed team of six in financial reporting, cash flow projections, return calculations, treasury, tax, and accounting for five opportunistic real estate preferred equity platforms

Led 4-6 people team with responsibilities including: fund operations/financial reporting for PE/VC firms; managed six clients with 5-7 staff per team; closed three funds ($800MM to $1B); offered Fund Controller role at two PE firms involved with work.